We are live on ! Find out more
RYTM icon

Rhythm Pharmaceuticals
RYTM

66 hedge funds and large institutions have $672M invested in Rhythm Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 66 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

89.91% more ownership

Funds ownership: 0% → 89.91% (+90%)

Holders
66
Holders Change
+66
Holders Change %
–
% of All Funds
1.5%
Holding in Top 10
4
Holding in Top 10 Change
+4
Holding in Top 10 Change %
% of All Funds
0.09%
New
66
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NMC
NEA Management Company
Maryland
+$130M
2
O
OrbiMed
New York
+$76.7M
3
MAM
MPM Asset Management
Massachusetts
+$71.3M
4
BBA
Baker Bros. Advisors
New York
+$54.2M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$34.4M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$143M +$130M +4,912,306 New
TG
2
TRV GP
Massachusetts
$116M +$105M +3,981,437 New
MAM
3
MPM Asset Management
Massachusetts
$78.4M +$71.3M +2,696,392 New
BBA
4
Baker Bros. Advisors
New York
$59.5M +$54.2M +2,049,020 New
O
5
OrbiMed
New York
$43.5M +$76.7M +2,901,295 New
Fidelity Investments
6
Fidelity Investments
Massachusetts
$37.9M +$34.4M +1,302,600 New
Janus Henderson Group
7
Janus Henderson Group
United Kingdom
$21.9M +$20M +755,160 New
PA
8
Perceptive Advisors
New York
$21.7M +$19.7M +745,135 New
DM
9
Deerfield Management
New York
$16.9M +$15.4M +582,010 New
Wellington Management Group
10
Wellington Management Group
Massachusetts
$15.8M +$14.4M +545,256 New
EC
11
EcoR1 Capital
California
$15.4M +$14M +530,161 New
Vanguard Group
12
Vanguard Group
Pennsylvania
$13.9M +$12.6M +477,433 New
ACH
13
ArrowMark Colorado Holdings
Colorado
$13.5M +$12.3M +464,109 New
BlackRock
14
BlackRock
New York
$10.5M +$9.52M +360,071 New
T. Rowe Price Associates
15
T. Rowe Price Associates
Maryland
$8.84M +$8.04M +304,127 New
Franklin Resources
16
Franklin Resources
California
$7.17M +$6.53M +246,900 New
Citadel Advisors
17
Citadel Advisors
Florida
$5.87M +$5.34M +201,828 New
FCMI
18
Foresite Capital Management IV
California
$5.09M +$4.63M +175,000 New
Federated Hermes
19
Federated Hermes
Pennsylvania
$4.36M +$3.97M +150,000 New
Geode Capital Management
20
Geode Capital Management
Massachusetts
$3.6M +$3.27M +123,795 New
JP Morgan Chase
21
JP Morgan Chase
New York
$3.43M +$3.12M +117,977 New
State Street
22
State Street
Massachusetts
$2.83M +$2.57M +97,294 New
Point72 Asset Management
23
Point72 Asset Management
Connecticut
$2.33M +$2.12M +80,000 New
Northern Trust
24
Northern Trust
Illinois
$2.27M +$2.07M +78,181 New
RSCM
25
Rock Springs Capital Management
Maryland
$2.08M +$1.89M +71,500 New
1
2 3

RYTM Hedge Fund Activity: Q4 2017 in Review

66 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Rhythm Pharmaceuticals (RYTM) for Q4 2017, worth a combined $672M.

Buyers outnumbered sellers: 66 funds opened new RYTM positions and 0 closed out — a net gain of 66 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was NEA Management Company, opening a new position worth an estimated $130M.

  • 66 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q4 2017, up from 0 in Q3 2017.
  • Funds reported $672M of Rhythm Pharmaceuticals stock for Q4 2017.
  • 66 funds opened new Rhythm Pharmaceuticals positions in Q4 2017 and 0 closed out, a net change of +66 holders.
  • The largest Rhythm Pharmaceuticals buyer in Q4 2017 was NEA Management Company, an estimated $130M added.

Based on aggregated 13F filings for Q4 2017.